TNFSF13 and myeloid sarcoma: However, in MS, the trial had to be aborted as patients treated with Atacicept experienced increased relapse frequency compared to placebo (23), suggesting that some BAFF/APRIL dependent B cell subsets may have beneficial effects on MS pathology.